TY - JOUR T1 - Therapeutic opportunities in neuroblastoma using nanotechnology JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther DO - 10.1124/jpet.118.255067 SP - jpet.118.255067 AU - Carlos Rodriguez-Nogales AU - Rosa Noguera AU - COUVREUR Patrick AU - Maria J J Blanco-Prieto Y1 - 2019/01/01 UR - http://jpet.aspetjournals.org/content/early/2019/01/11/jpet.118.255067.abstract N2 - Neuroblastoma is the most common extracranial solid tumor that preferentially occurs in preschoolers. Its characteristic aggressiveness and heterogeneous clinical behavior is especially visible in relapsed or refractory cases and hampers the therapeutic success. Although the introduction of novel antitumor agents such as dinutuximab, isotretinoin, irinotecan or I-131-MIBG has increased survival, the situation in high-risk neuroblastoma is still dismal. Moreover, treatment is particularly aggressive in these patients, leading to short- and long-term toxicities. The extensive research performed using nanotechnology in recent decades has prompted its application of nanotechnology as a therapeutic alternative to common limitations of conventional chemotherapy. Nevertheless, the therapeutic role of nanomedicine in pediatric tumors like NB is not fully elucidated and to this date, only albumin-bound paclitaxel nanoparticles have reached clinic stages. In this review we summarize the neuroblastoma current therapeutic strategies with special attention to the use of nanomedicine. We also highlight the pre-clinical studies on passive and active targeting nanodelivery of therapeutics in experimental NB models. ER -